About Us
Telix Pharmaceuticals was created to deliver on the promise of nuclear medicine
The field of nuclear medicine has historically lacked clinical momentum and commitment to late-stage product development. Our goal is to rectify this for the benefit of patients.
)
Take a PSMA journey with Telix at EAU22
24 June 2022 – Take a journey with Telix at EAU 2022 to discover how PSMA diagnostics are changing the...
Telix at ANZSNM Annual Scientific Meeting 2022
9 May 2022 – Corporate Spotlight | Telix supporting and participating in Australian and New Zealand Society of Nuclear Medicine...
First Patient Dosed in Phase II Renal Cancer Theranostics Study
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 5 May 2022. Telix announces that a first patient has been dosed in...
Telix Further Strengthens European Distribution Network for Illuccix
Melbourne (Australia) and Liège (Belgium)– 22 April 2022. Telix announces agreements with Avanço and THP for the distribution of Telix’s...